KW-6356 is a novel adenosine A 2A (A 2A) receptor antagonist/inverse agonist, and its efficacy as monotherapy in Parkinson's disease (PD) patients has been reported. Istradefylline is a first …

2023年12月1日 · KW-6356 is a novel, selective, nonxanthine A 2A receptor antagonist/inverse agonist with about 100-times higher affinity than istradefylline for the human A 2A receptor [20].

Introduction: KW-6356 is a novel selective adenosine A 2A receptor antagonist/inverse agonist. We evaluated the efficacy and safety of KW-6356 as monotherapy in patients with early, …

2022年7月25日 · Kyowa Kirin has discontinued the clinical development of its investigational treatment, KW-6356, for Parkinson’s disease, despite Phase 2 clinical trial data showing …

The adenosine A 2A receptor antagonist/inverse agonist, KW-6356 has been shown to be effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to L …

KW-6356 is a novel adenosine A (A) receptor antagonist/inverse agonist, and its efficacy as monotherapy in Parkinson’s disease (PD) patients has been reported. Istradefylline is a first …

2023年7月1日 · We examined the effects of combination of KW-6356 with L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets. Oral administration of …

2023年5月1日 · Kyowa Kirin’s KW-6356, or sipagladenant , is a non-xanthine A 2A receptor intended to treat Parkinson’s disease. Unlike Kyowa Kirin’s recently US-approved neutral …

2022年9月18日 · In a phase 2b randomized, placebo-controlled study (NCT03703570), KW-6356, a selective antagonist of adenosine A2A receptors developed by Kyowa Hakko Kirin, …

2020年10月21日 · KW-6356 has a high affinity and selectivity for adenosine A2A receptors, and is therefore expected to obtain approval for wider indications as the next generation of …